LPL Receptor Inhibitor

SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

Cudetaxestat (BLD-0409; PAT-409) is an orally active and noncompetitive autotaxin (ATX) inhibitor. Cudetaxestat inhibits the activity of ATX, reduces the production of LPA, and thereby blocks the signal transduction of the ATX-LPA axis. Cudetaxestat can still maintain nanomolar-level biochemical efficacy even when the concentration of the LPC substrate increases. Cudetaxestat can be used for the study of various diseases related to LPA including fibrosis, tumor metastasis, inflammation and autoimmune diseases, etc.

A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [³H]dhS1P increase.

S1PR2 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

S1PR1 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC₅₀ of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC₅₀ of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis.

SLB1122168 is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC₅₀ of 94 nM. SLB1122168 induces lymphopenia in circulating lymphocytes in mice and rats.

Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC₅₀ value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer.

S1PR5 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy.

Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC₅₀ of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis.

Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

S1pr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for S1pr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system.

Spns2-IN-1 is a potent inhibitor of Spns2-dependent S1P transport (Spns2), with IC₅₀ of 1.4±0.3 μM that plays an important role in immune response.

AB1 is a highly selective S1P2 receptor antagonist (IC₅₀=3.5 nM). AB1 inhibits sphingosine-1-phosphate (S1P) signaling, suppressing tumor cell migration, angiogenesis, and profibrotic mediator CTGF expression while inducing apoptosis. AB1 is promising for research of solid tumors.

S1pr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for S1pr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

S1pr5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for S1pr5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

RBM10-8 is irreversible inhibitor of recombinant  human sphingosine-1-phosphate lyase (hS1PL) . Sphingosine-1-phosphate (S1P) is a sphingolipid (SL) that acts as a signaling molecule regulating diverse cellular processes such as cell proliferation and differentiation, angiogenesis, immune function, inflammation, and development.